Clinical-stage cardiometabolic biotech developing next-generation oral and injectable peptide therapies for obesity and related metabolic conditions, led by an oral formulation of ecnoglutide and a portfolio of amylin-based candidates.
The candidate is an oral version of ecnoglutide, a subcutaneous formulation of which is approved in China for type 2 diabetes and weight management. Pfizer owns commercialization rights for ecnoglutide in the Asian country.